Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor
Open Access
- 14 November 2025
- journal article
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1 (3)
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Parker Institute for Cancer Immunotherapy (NIH-RO1AI51321)
- Parker Institute for Cancer Immunotherapy (U54CA244711)
This publication has 68 references indexed in Scilit:
- Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cellsCell, 2023
- Improving cell and gene therapy safety and performance using next-generation Nanoplasmid vectorsMolecular Therapy Nucleic Acids, 2023
- CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapyComputational and Structural Biotechnology Journal, 2020
- Biology of IL-2 and its therapeutic modulation: Mechanisms and strategiesJournal of Leukocyte Biology, 2018
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18Cell Reports, 2017
- Interleukin-2: Biology, Design and ApplicationTrends in Immunology, 2015
- Biochemical Mechanisms of IL-2–Regulated Fas-Mediated T Cell ApoptosisImmunity, 1998
- Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartmentImmunity, 1995
- Ulcerative colitis-like disease in mice with a disrupted interleukin-2 geneCell, 1993
- A continuous T-cell line from a patient with S zary syndromeArchives of Dermatological Research, 1987